<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="systematic-review" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Med.</journal-id>
<journal-title>Frontiers in Medicine</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Med.</abbrev-journal-title>
<issn pub-type="epub">2296-858X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmed.2024.1295217</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Medicine</subject>
<subj-group>
<subject>Systematic Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>A systematic review assessing the potential use of cystatin c as a biomarker for kidney disease in people living with HIV on antiretroviral therapy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Hanser</surname> <given-names>Sidney</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1724481/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Choshi</surname> <given-names>Joel</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2508032/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Mokoena</surname> <given-names>Haskly</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2595142/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Mabhida</surname> <given-names>Sihle E.</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1964363/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Mchiza</surname> <given-names>Zandile J. R.</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1840785/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Moetlediwa</surname> <given-names>Marakiya T.</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Muvhulawa</surname> <given-names>Ndivhuwo</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1883103/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Nkambule</surname> <given-names>Bongani B.</given-names></name>
<xref ref-type="aff" rid="aff6"><sup>6</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2259310/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Ndwandwe</surname> <given-names>Duduzile</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1066718/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Nqebelele</surname> <given-names>Unati</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff7"><sup>7</sup></xref>
<xref ref-type="aff" rid="aff8"><sup>8</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2510632/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Kengne</surname> <given-names>Andr&#x00E9; P.</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff7"><sup>7</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1543553/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Dludla</surname> <given-names>Phiwayinkosi V.</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<xref ref-type="aff" rid="aff9"><sup>9</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/827560/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Physiology and Environmental Health, University of Limpopo</institution>, <addr-line>Sovenga</addr-line>, <country>South Africa</country></aff>
<aff id="aff2"><sup>2</sup><institution>Non-Communicable Diseases Research Unit, South African Medical Research Council</institution>, <addr-line>Cape Town</addr-line>, <country>South Africa</country></aff>
<aff id="aff3"><sup>3</sup><institution>School of Public Health, University of the Western Cape</institution>, <addr-line>Bellville</addr-line>, <country>South Africa</country></aff>
<aff id="aff4"><sup>4</sup><institution>Department of Biochemistry, North-West University</institution>, <addr-line>Mmabatho</addr-line>, <country>South Africa</country></aff>
<aff id="aff5"><sup>5</sup><institution>Cochrane South Africa, South African Medical Research Council</institution>, <addr-line>Cape Town</addr-line>, <country>South Africa</country></aff>
<aff id="aff6"><sup>6</sup><institution>School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal</institution>, <addr-line>Durban</addr-line>, <country>South Africa</country></aff>
<aff id="aff7"><sup>7</sup><institution>Department of Medicine, University of Cape Town</institution>, <addr-line>Cape Town</addr-line>, <country>South Africa</country></aff>
<aff id="aff8"><sup>8</sup><institution>Department of Internal Medicine, University of the Witwatersrand</institution>, <addr-line>Johannesburg</addr-line>, <country>South Africa</country></aff>
<aff id="aff9"><sup>9</sup><institution>Department of Biochemistry and Microbiology, University of Zululand</institution>, <addr-line>KwaDlangezwa</addr-line>, <country>South Africa</country></aff>
<author-notes>
<fn fn-type="edited-by" id="fn0001"><p>Edited by: Sree Bhushan Raju, Nizam's Institute of Medical Sciences, India</p></fn>
<fn fn-type="edited-by" id="fn0002"><p>Reviewed by: Emmanuel Agaba, Morgan State University, United States</p><p>Bowen Zhu, Fudan University, China</p></fn>
<corresp id="c001">&#x002A;Correspondence: Sidney Hanser, <email>sidney.hanser@ul.ac.za</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>19</day>
<month>03</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>11</volume>
<elocation-id>1295217</elocation-id>
<history>
<date date-type="received">
<day>03</day>
<month>10</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>02</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2024 Hanser, Choshi, Mokoena, Mabhida, Mchiza, Moetlediwa, Muvhulawa, Nkambule, Ndwandwe, Nqebelele, Kengne and Dludla.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Hanser, Choshi, Mokoena, Mabhida, Mchiza, Moetlediwa, Muvhulawa, Nkambule, Ndwandwe, Nqebelele, Kengne and Dludla</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>The introduction of antiretroviral therapy (ART) has significantly prolonged the lifespan of people living with human immunodeficiency virus (PLWH). However, the sustained use of this drug regimen has also been associated with a cluster of metabolic anomalies, including renal toxicity, which can lead to the development of kidney diseases. In this study, we reviewed studies examining kidney disease in PLWH sourced from electronic databases such as PubMed/MEDLINE, Scopus, and Google Scholar, as well as gray literature. The narrative synthesis of data from these clinical studies demonstrated that the serum levels of cystatin C remained unchanged or were not affected in PLWH on ART, while the creatinine-based glomerular filtration rate (GFR) fluctuated. In fact, some of the included studies showed that the creatinine-based GFR was increased in PLWH taking tenofovir disoproxil fumarate-containing ART, perhaps indicating that the use of both cystatin C- and creatinine-based GFRs is vital to monitor the development of kidney disease in PLWH. Clinical data summarized within this study indicate the potential detrimental effects of tenofovir-based ART regimens in causing renal tubular injury, while highlighting the possible beneficial effects of dolutegravir-based ART on improving the kidney function in PLWH. However, the summarized literature remains limited, while further clinical studies are required to provide insights into the potential use of cystatin C as a biomarker for kidney disease in PLWH.</p>
</abstract>
<kwd-group>
<kwd>HIV</kwd>
<kwd>highly active antiretroviral therapy</kwd>
<kwd>biomarker</kwd>
<kwd>cystatin C</kwd>
<kwd>kidney function</kwd>
<kwd>nephropathy</kwd>
</kwd-group>
<counts>
<fig-count count="1"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="68"/>
<page-count count="9"/>
<word-count count="7060"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Nephrology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<label>1</label>
<title>Introduction</title>
<p>Chronic kidney disease is a progressive medical condition that affects approximately 10% of the global population, with over 800 million reported cases worldwide (<xref ref-type="bibr" rid="ref1">1</xref>). The International Society of Nephrology Global Health Atlas survey for Africa has estimated the prevalence of this condition to be similarly high in South Africa, especially aggravated/exacerbated by socioeconomic inequalities (<xref ref-type="bibr" rid="ref2">2</xref>). Older individuals, including people with other disease conditions such as diabetes mellitus, hypertension, and human immunodeficiency virus (HIV), present with the greatest burden of kidney disease (<xref ref-type="bibr" rid="ref3">3</xref>). Prominent features of chronic kidney disease include accelerated fibrosis and a decline in the rate of glomerular filtration, which can progress to end-stage kidney diseases and is associated with new-onset kidney injury (<xref ref-type="bibr" rid="ref4">4</xref>). End-stage kidney failure occurs when the kidneys are no longer able to meet day-to-day requirements, while acute kidney injury is considered an abrupt reduction in the kidney function, which incorporates both structural damage and functional loss (<xref ref-type="bibr" rid="ref5">5</xref>). Chronic kidney disease has become even more prevalent among people living with HIV (PLWH) compared to the general population and is correlated with an increased risk of adverse outcomes, such as heart failure, diabetes mellitus, and cardiovascular disease (<xref ref-type="bibr" rid="ref6 ref7 ref8">6&#x2013;8</xref>). Because of the many developing consequences associated with the sustained use of antiretroviral therapy (ART) (<xref ref-type="bibr" rid="ref9">9</xref>, <xref ref-type="bibr" rid="ref10">10</xref>), there has been an enhanced need to understand the status of kidney disease in PLWH (<xref ref-type="bibr" rid="ref11 ref12 ref13">11&#x2013;13</xref>).</p>
<p>There is no argument that the effective use of ART has certainly prolonged the lifespan of PLWH (<xref ref-type="bibr" rid="ref14">14</xref>). However, disparities linked with treatment adherence, dose selection, and the presence of other chronic conditions could contribute to disruptions in the organ function (<xref ref-type="bibr" rid="ref15">15</xref>), including kidney toxicity (<xref ref-type="bibr" rid="ref6">6</xref>, <xref ref-type="bibr" rid="ref7">7</xref>). The common methods of assessing the renal function in PLWH include the serum creatinine-based estimated glomerular filtration rate (eGFR) or creatinine clearance and/or urinalysis of proteinuria, glucose, or phosphate excretion (<xref ref-type="bibr" rid="ref16">16</xref>, <xref ref-type="bibr" rid="ref17">17</xref>). However, evidence points to the limitations of these methods, as they may not be sensitive enough to detect kidney toxicity in PLWH (<xref ref-type="bibr" rid="ref18 ref19 ref20">18&#x2013;20</xref>).</p>
<p>Currently, growing evidence underscores the importance of making use of other alternative markers, such as serum cystatin C, to estimate GFR or renal tubular injury in PLWH (<xref ref-type="bibr" rid="ref21">21</xref>, <xref ref-type="bibr" rid="ref22">22</xref>). Human cystatin C is a low-molecular-weight cysteine-rich protein that is synthesized by almost all tissues of the body (<xref ref-type="bibr" rid="ref23">23</xref>). Despite the substantiated evidence that efficient kidneys can regulate serum cystatin C concentration to meet body&#x2019;s homeostatic requirements, there is growing evidence to suggest an inverse correlation between GFR and serum cystatin C (<xref ref-type="bibr" rid="ref20">20</xref>, <xref ref-type="bibr" rid="ref22">22</xref>, <xref ref-type="bibr" rid="ref24">24</xref>). Most recent evidence also shows that cystatin C could effectively identify high-risk chronic kidney disease individuals that may not have been detected by creatinine and enhanced eGFR-based risk stratification (<xref ref-type="bibr" rid="ref25">25</xref>). However, it has also been argued that the available literature does not encourage the use of cystatin C or cystatin C-based equations to estimate the GFR in PLWH (<xref ref-type="bibr" rid="ref26">26</xref>). This is compounded by the lack of consideration for other hypotheses regarding the potential detrimental effects of certain ART regimens on the kidney function in PLWH (<xref ref-type="bibr" rid="ref27">27</xref>, <xref ref-type="bibr" rid="ref28">28</xref>). Thus, this aspect indicates the necessity for further research to scrutinize the relevance of using cystatin C or its relation to other biomarkers of kidney injury, such as creatinine, in PLWH on ART. Therefore, this report aimed to understand whether serum levels of cystatin C may be potentially used as a plausible biomarker to assess the renal function through the GFR. The current study, therefore, makes use of a systematic approach to identify and discuss clinical studies that provide information on the potential use of cystatin C as a biomarker for kidney disease or a risk thereof in PLWH. The analysis and discussion extend to evaluating whether ART has a negative or positive impact on the circulating levels of this protein in PLWH.</p>
</sec>
<sec sec-type="methods" id="sec2">
<label>2</label>
<title>Methodology</title>
<sec id="sec3">
<label>2.1</label>
<title>Literature search strategy</title>
<p>This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (<xref ref-type="bibr" rid="ref29">29</xref>), although a meta-analysis was not conducted for this particular study (<xref ref-type="supplementary-material" rid="SM1">Supplementary File 1</xref>). Briefly, a systematic literature search was conducted using major online databases, such as PubMed/MEDLINE, Scopus, and Google Scholar, to identify clinical studies reporting on any association between cystatin C and kidney disease in PLWH on HARRT. The search strategy was compiled using a combination of the following keywords or Medical Subject Headings (MeSH); &#x201C;cystatin C,&#x201D; &#x201C;ART,&#x201D; &#x201C;glomerular filtration rate,&#x201D; &#x201C;creatinine,&#x201D; and &#x201C;HIV&#x201D; including the most relevant synonyms (<xref ref-type="supplementary-material" rid="SM1">Supplementary File 2</xref>). All the retrieved references were reviewed for additional relevant studies. This literature search was run without limitation until December 2023, for an adequate update on the literature. While this protocol was not registered with PROSPERO (International Prospective Register for Systematic Reviews), we conducted thorough searches of this database and any other relevant registries to ensure that our study did not duplicate existing research.</p>
</sec>
<sec id="sec4">
<label>2.2</label>
<title>Study selection by inclusion and exclusion criteria</title>
<p>Study selection was primarily conducted by two independent authors, focusing only on clinical articles meeting the criteria. Briefly, the inclusion criteria extend to articles that presented clinical research on kidney diseases, gray literature, pre-prints, and index journal publications, focusing on cystatin C and kidney disease in PLWH on ART. Exclusions were reviews, letters, editorials, notes, non-human studies, incomplete or unpublished studies, and those irrelevant to the scope (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The following populations, interventions/exposures, comparators, outcomes (PICO/PECO) were used:</p>
<list list-type="simple">
<list-item><p>P: PLWH on ART</p></list-item>
<list-item><p>I/E: Levels of cystatin C (in PLWH on ART)</p></list-item>
<list-item><p>C: PLWH not on ART or treatment naive individuals</p></list-item>
<list-item><p>O: Markers/indicators of renal function.</p></list-item>
</list>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Flow diagram of the study selection process. Briefly, a systematic search of major electron databases retrieved 80 records, of which 81 were excluded for being duplicates or for not meeting the inclusion criteria. Notably, 20 studies (<italic>n</italic> =&#x2009;20) were included and discussed within the manuscript, reporting on cystatin C and kidney disease in people living with HIV (PLWH) on antiretroviral therapy. Studies were mainly excluded because they were out of scope, one is a thesis or not reporting on the modulation of cystatin C.</p>
</caption>
<graphic xlink:href="fmed-11-1295217-g001.tif"/>
</fig>
</sec>
<sec id="sec5">
<label>2.3</label>
<title>Data extraction and quality assessment</title>
<p>Data extraction was independently conducted by two authors, with a primary focus on eligible studies reporting any association between cystatin C and kidney disease in PLWH on ART. The extracted items included author details, the year the study was published, the age of participants, the type of ART regimen, and the main findings reported in each report. Data reporting on other factors, such as ethnicity and existing chronic comorbidities, were also extracted, if available. The quality of included studies was also independently assessed by two authors, using the Downs and Black Checklist (<xref ref-type="bibr" rid="ref30">30</xref>, <xref ref-type="bibr" rid="ref31">31</xref>). The checklist comprises 27 questions and 4 domains, allowing studies to be assessed as either good or excellent (<xref ref-type="bibr" rid="ref29">29</xref>, <xref ref-type="bibr" rid="ref30">30</xref>, <xref ref-type="bibr" rid="ref32 ref33 ref34 ref35">32&#x2013;35</xref>); of these, 12 received a score of good (<xref ref-type="bibr" rid="ref26">26</xref>, <xref ref-type="bibr" rid="ref28">28</xref>, <xref ref-type="bibr" rid="ref31">31</xref>, <xref ref-type="bibr" rid="ref36 ref37 ref38 ref39 ref40 ref41 ref42 ref43 ref44">36&#x2013;44</xref>) and 3 were rated as fair (<xref ref-type="bibr" rid="ref25">25</xref>, <xref ref-type="bibr" rid="ref27">27</xref>, <xref ref-type="bibr" rid="ref45">45</xref>). <xref ref-type="supplementary-material" rid="SM1">Supplementary File 3</xref> shows that included studies had low reporting bias with a mean score of 10 out of a possible score of 11 (overall agreement 85.67%, kappa&#x2009;=&#x2009;0.71), excellent external validity with a mean score of 3 out of 3 (overall agreement 39.13%, kappa&#x2009;=&#x2009;0.13), good internal validity with a mean score of 5 out of 7 (overall agreement 65.22%, kappa&#x2009;=&#x2009;0.34), and low risk selection bias with a mean score of 4 out of possible 6 (overall agreement 56.51%, kappa&#x2009;=&#x2009;0.19).</p>
</sec>
</sec>
<sec sec-type="results" id="sec6">
<label>3</label>
<title>Results</title>
<sec id="sec7">
<label>3.1</label>
<title>General characteristics and quality of included studies</title>
<p>Briefly, a systematic search yielded nine qualifying clinical studies, published between 2008 and 2023 (<xref ref-type="table" rid="tab1">Table 1</xref>). In terms of regional distribution, China contributed two qualifying studies, while evidence from other countries was broadly spread; the majority of studies were from the United States (<italic>n</italic>&#x2009;=&#x2009;5), followed by Germany (<italic>n</italic>&#x2009;=&#x2009;2), Nigeria (<italic>n</italic>&#x2009;=&#x2009;2), Italy (<italic>n</italic>&#x2009;=&#x2009;2), and China (<italic>n</italic>&#x2009;=&#x2009;2), while other countries presented with one report, including France, Indonesia, Japan, Serbia, Spain, Poland, and the United Kingdom (<xref ref-type="table" rid="tab1">Table 1</xref>). The study design included four randomized controlled trials, nine observational studies, four cross-sectional studies, one case&#x2013;control, and two retrospective designs (<xref ref-type="table" rid="tab1">Table 1</xref>). The study population involved PLWH on ART, with a sample size ranging from as low as <italic>n</italic>&#x2009;=&#x2009;15 to as high as <italic>n</italic>&#x2009;=&#x2009;670. Most studies (<italic>n</italic>&#x2009;=&#x2009;10) encompassed adults with mean ages ranging from 34 to 53&#x2009;years, one study involved young adults with a mean age of 17&#x2009;years, and one study reported on children with a mean age of 12&#x2009;years (<xref ref-type="table" rid="tab1">Table 1</xref>). The study duration ranged from as low as 12&#x2009;weeks to a maximum of 8&#x2009;years of ART monitoring. However, it was also clear that most studies (<italic>n</italic>&#x2009;=&#x2009;4) had a duration of approximately 48&#x2009;weeks (<xref ref-type="table" rid="tab1">Table 1</xref>). The quality of the included studies (<italic>n</italic>&#x2009;=&#x2009;20) was assessed using the Downs and Black Checklist. Briefly, most of the studies (<italic>n</italic>&#x2009;=&#x2009;15) were rated as having good quality of evidence, with two studies classified as having excellent quality evidence, scoring 25 and 27 out of 28 total scores (<xref ref-type="bibr" rid="ref32">32</xref>, <xref ref-type="bibr" rid="ref45">45</xref>). Three of the 20 included studies were rated as fair quality studies, with scores of 17, 18, and 19 out of 28 possible scores (<xref ref-type="bibr" rid="ref39">39</xref>, <xref ref-type="bibr" rid="ref43">43</xref>, <xref ref-type="bibr" rid="ref50">50</xref>). Based on the different domains, overall, there was an excellent reporting bias as indicated by a mean score of 10 (9&#x2013;11) out of 11 possible scores, with a slight rater agreement between the two independent reviewers as indicated by a Cohen&#x2019;s Kappa value (K) of 0.020. Furthermore, the studies exhibited overall good external validity with a mean score of 3 (0&#x2013;3) out of 3 total scores and a fair rater agreement value of K&#x2009;=&#x2009;0.30, and they also demonstrated overall good internal validity with a mean score of 5 (4&#x2013;6) out of 7 total scores and a moderate rater agreement value of K&#x2009;=&#x2009;0.42. The majority of the studies (<italic>n</italic>&#x2009;=&#x2009;17) had good power (&#x2265;90%), indicating that these studies had no type 2 error, with a median score of 0.85 (0&#x2013;1) (<xref ref-type="supplementary-material" rid="SM1">Supplementary File 3</xref>).</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Overview of clinical evidence linking cystatin C and kidney disease in people living with human immunodeficiency virus (PLWH).</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">References</th>
<th align="left" valign="middle">Country</th>
<th align="left" valign="middle">Type of study</th>
<th align="left" valign="middle">Study population, including age</th>
<th align="left" valign="middle">Intervention, including ART regimen and treatment duration</th>
<th align="left" valign="middle">Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Jones et al. (<xref ref-type="bibr" rid="ref32">32</xref>)</td>
<td align="left" valign="top">United States</td>
<td align="left" valign="top">Cross-sectional study</td>
<td align="left" valign="top">PLWH on ART (<italic>n</italic> =&#x2009;250), with a mean age of 41&#x2009;years</td>
<td align="left" valign="top">Received ART for at least 1&#x2009;year</td>
<td align="left" valign="top">Approximately 2.4% of the participants showed lower eGFRscr compared to approximately 15% showing low estimated glomerular filtration rate from creatinine (eGFR<sub>cystC</sub>)</td>
</tr>
<tr>
<td align="left" valign="top">Mauss et al. (<xref ref-type="bibr" rid="ref33">33</xref>)</td>
<td align="left" valign="top">Germany</td>
<td align="left" valign="top">Observational study</td>
<td align="left" valign="top">PLWH on ART (<italic>n</italic> =&#x2009;92), with a mean age of 37&#x2009;years</td>
<td align="left" valign="top">Received ART for 3&#x2009;years</td>
<td align="left" valign="top">Cystatin C correlated with HIV RNA and CD4+ T-cell count, but was suppressed after initiation of ART</td>
</tr>
<tr>
<td align="left" valign="top">Falasca et al. (<xref ref-type="bibr" rid="ref34">34</xref>, <xref ref-type="bibr" rid="ref35">35</xref>)</td>
<td align="left" valign="top">Italy</td>
<td align="left" valign="top">Observational study</td>
<td align="left" valign="top">PLWH on ART (<italic>n</italic> =&#x2009;15) with higher cardiovascular disease risk, with a mean age of 51&#x2009;years</td>
<td align="left" valign="top">Received different types of ART for &#x2265;12&#x2009;months</td>
<td align="left" valign="top">Raised plasma levels of cystatin C were consistent with increased concentrations of leptin, interleukin-6/-18, and hypoadiponectinemia</td>
</tr>
<tr>
<td align="left" valign="top">Inker et al. (<xref ref-type="bibr" rid="ref36">36</xref>)</td>
<td align="left" valign="top">United States</td>
<td align="left" valign="top">Observational study</td>
<td align="left" valign="top">PLWH on ART (<italic>n</italic> =&#x2009;200), with a mean age of 48&#x2009;years</td>
<td align="left" valign="top">Received ART with or without tenofovir, within 6&#x2009;months after confirmation of HIV status</td>
<td align="left" valign="top">Cystatin C equation was not more accurate than the creatinine equation. The creatinine&#x2013;cystatin C equation was more accurate than the cystatin C equation</td>
</tr>
<tr>
<td align="left" valign="top">Overton et al. (<xref ref-type="bibr" rid="ref37">37</xref>)</td>
<td align="left" valign="top">United States</td>
<td align="left" valign="top">Observational study</td>
<td align="left" valign="top">PLWH on ART (<italic>n</italic> =&#x2009;670) with renal dysfunction, with a mean age of 41&#x2009;years</td>
<td align="left" valign="top">Received ART-containing tenofovir or ritonavir or both</td>
<td align="left" valign="top">Totally, 40% of subjects had renal dysfunction; 3.3% had chronic kidney disease. Elevated cystatin C was present in 18% of subjects</td>
</tr>
<tr>
<td align="left" valign="top">Bhasin et al. (<xref ref-type="bibr" rid="ref38">38</xref>)</td>
<td align="left" valign="top">United States</td>
<td align="left" valign="top">Observational study</td>
<td align="left" valign="top">PLWH on ART (<italic>n</italic> =&#x2009;187), with a mean age of 49&#x2009;years</td>
<td align="left" valign="top">Received ART-containing tenofovir or cobicistat</td>
<td align="left" valign="top">eGFR<sub>CystC</sub> bias and accuracy were strongly associated with the use of ART, HIV RNA suppression, and percentages of activated CD4 or CD8 T-cells</td>
</tr>
<tr>
<td align="left" valign="top">Yoshino et al. (<xref ref-type="bibr" rid="ref39">39</xref>)</td>
<td align="left" valign="top">Japan</td>
<td align="left" valign="top">Retrospective design</td>
<td align="left" valign="top">PLWH on ART (<italic>n</italic> =&#x2009;18), with a mean age of 44&#x2009;years</td>
<td align="left" valign="top">Received ART-containing dolutegravir for &#x2265;12&#x2009;months</td>
<td align="left" valign="top">While the level of eGFR<sub>CystC</sub> was not changed, that of the estimated glomerular filtration rate from creatinine (eGFRscr) fluctuated</td>
</tr>
<tr>
<td align="left" valign="top">Dragovi&#x0107; et al. (<xref ref-type="bibr" rid="ref40">40</xref>)</td>
<td align="left" valign="top">Serbia</td>
<td align="left" valign="top">Cross-sectional study</td>
<td align="left" valign="top">PLWH on ART (<italic>n</italic> =&#x2009;33) with metabolic syndrome, with a mean age of 46&#x2009;years</td>
<td align="left" valign="top">Received ART for at least 6&#x2009;months</td>
<td align="left" valign="top">There was a positive correlation of cystatin C and C-reactive protein in PLWH with metabolic syndrome, compared to those without the metabolic syndrome</td>
</tr>
<tr>
<td align="left" valign="top">Szymczak et al. (<xref ref-type="bibr" rid="ref41">41</xref>)</td>
<td align="left" valign="top">Poland</td>
<td align="left" valign="top">Observational study</td>
<td align="left" valign="top">PLWH on ART (<italic>n</italic> =&#x2009;119) without a history of kidney dysfunction, with a mean age of 40&#x2009;years</td>
<td align="left" valign="top">Received tenofovir disoproxil fumarate, protease inhibitors or 3&#x2009;years</td>
<td align="left" valign="top">Low current CD4+ cell count was consistent with raised levels of cystatin C level. Use of tenofovir or other potentially nephrotoxic antiretroviral drugs did not have any impact on urinary cystatin C levels</td>
</tr>
<tr>
<td align="left" valign="top">Casado et al. (<xref ref-type="bibr" rid="ref24">24</xref>)</td>
<td align="left" valign="top">Spain</td>
<td align="left" valign="top">Observational study</td>
<td align="left" valign="top">PLWH (<italic>n</italic> =&#x2009;288) on ART, with a mean age of 50&#x2009;years</td>
<td align="left" valign="top">Received dual regimens that included (dolutegravir + rilpivirine, 92; dolutegravir + darunavir/cobicistat, 23; dolutegravir, 26; cobicistat, 19; control group, 128) for 48&#x2009;weeks</td>
<td align="left" valign="top">eGFRscr was reduced in PLWH taking two transporter inhibitors. This was similar to those taking dolutegravir or cobicistat. Similarly, the evolution of proteinuria and tubular dysfunction was apparent in all the groups, albeit no significant changes in eGFR<sub>CystC</sub></td>
</tr>
<tr>
<td align="left" valign="top">Rashbaum et al. (<xref ref-type="bibr" rid="ref45">45</xref>)</td>
<td align="left" valign="top">United States</td>
<td align="left" valign="top">Randomized controlled trial</td>
<td align="left" valign="top">PLWH (<italic>n</italic> =&#x2009;725) on ART, with a mean age of 34&#x2009;years</td>
<td align="left" valign="top">Received single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir vs. darunavir/cobicistat + emtricitabine/tenofovir disoproxil fumarate (control) alafenamide for 48&#x2009;weeks</td>
<td align="left" valign="top">Estimated glomerular filtration rate from serum cystatin C (eGFR<sub>CystC</sub>) remained unchanged between treatment groups. This was consistent with bone mineral density</td>
</tr>
<tr>
<td align="left" valign="top">Hamzah et al. (<xref ref-type="bibr" rid="ref42">42</xref>)</td>
<td align="left" valign="top">United Kingdom</td>
<td align="left" valign="top">Randomized controlled trial</td>
<td align="left" valign="top">PLWH (<italic>n</italic> =&#x2009;31) with a history of tenofovir disoproxil fumarate-associated proximal renal tubulopathy on ART, with a mean age of 53&#x2009;years</td>
<td align="left" valign="top">Received 1:1 to continue current antiretroviral therapy or initiate emtricitabine/ tenofovir alafenamide for 12&#x2009;weeks</td>
<td align="left" valign="top">eGFR<sub>CystC</sub> and eGFRscr were not affected, including other makers such as albuminuria, proteinuria, renal phosphate or urea handling, (fasting) urine osmolality, parathyroid hormone, and bone turnover markers</td>
</tr>
<tr>
<td align="left" valign="top">John et al. (<xref ref-type="bibr" rid="ref43">43</xref>)</td>
<td align="left" valign="top">Nigeria</td>
<td align="left" valign="top">Randomized controlled trial</td>
<td align="left" valign="top">PLWH on ART (<italic>n</italic> =&#x2009;200), with a mean age of 27&#x2009;years</td>
<td align="left" valign="top">Received ART-containing tenofovir or ritonavir or both</td>
<td align="left" valign="top">There was a significant difference between the values of creatinine, cystatin c, and urea recorded in PLWH on treatment</td>
</tr>
<tr>
<td align="left" valign="top">Priscilla et al. (<xref ref-type="bibr" rid="ref44">44</xref>)</td>
<td align="left" valign="top">Nigeria</td>
<td align="left" valign="top">Case&#x2013;control study</td>
<td align="left" valign="top">PLWH (<italic>n</italic> =&#x2009;100) on ART, with a mean age of 37&#x2009;years</td>
<td align="left" valign="top">Received lamivudine, stavudine, and nevirapine and monitored for no longer than 5&#x2009;years</td>
<td align="left" valign="top">Serum cystatin C levels were elevated in men, regardless of ART status. This was correlated with serum creatinine levels</td>
</tr>
<tr>
<td align="left" valign="top">Zhao et al. (<xref ref-type="bibr" rid="ref46">46</xref>)</td>
<td align="left" valign="top">China</td>
<td align="left" valign="top">Cross-sectional study</td>
<td align="left" valign="top">PLWH (<italic>n</italic> =&#x2009;172) on ART, with a mean age of 40&#x2009;years</td>
<td align="left" valign="top">Received tenofovir disoproxil fumarate + lamivudine + efavirenz, tenofovir disoproxil fumarate + plus lamivudine + ritonavir-boosted lopinavir, tenofovir disoproxil fumarate + lamivudine plus dolutegravir, or elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide fumarate, and monitored for 1&#x2009;year</td>
<td align="left" valign="top">eGFRscr alone was higher than eGFR calculated by the combination of serum creatinine and cystatin C, while that of eGFR<sub>CystC</sub> was lower than eGFR calculated from both markers. This indicates that eGFR calculated by the combination of serum creatinine and cystatin C is more accurate, than each marker alone</td>
</tr>
<tr>
<td align="left" valign="top">Hikasa et al. (<xref ref-type="bibr" rid="ref47">47</xref>)</td>
<td align="left" valign="top">Japan</td>
<td align="left" valign="top">Observational study</td>
<td align="left" valign="top">PLWH (<italic>n</italic> =&#x2009;63) on ART, with a mean age of 39&#x2009;years</td>
<td align="left" valign="top">Switched the antiretroviral drug from tenofovir disoproxil fumarate to tenofovir alafenamide, and exposures were 1.6 and 1.5&#x2009;years, respectively</td>
<td align="left" valign="top">Switching from tenofovir disoproxil fumarate to tenofovir alafenamide was an independent predictor of improved eGFR<sub>CystC</sub> slope</td>
</tr>
<tr>
<td align="left" valign="top">Lu et al. (<xref ref-type="bibr" rid="ref48">48</xref>)</td>
<td align="left" valign="top">China</td>
<td align="left" valign="top">Retrospective design</td>
<td align="left" valign="top">PLWH (<italic>n</italic> =&#x2009;138), over the mean age of 36&#x2009;years</td>
<td align="left" valign="top">Received dolutegravir + tenofovir disoproxil fumarate, dolutegravir only, or tenofovir disoproxil fumarate for 48&#x2009;weeks at most</td>
<td align="left" valign="top">Serum creatinine was significantly elevated in PLWH receiving dolutegravir + tenofovir disoproxil fumarate. Serum cystatin C and eGFR<sub>CystC</sub> in those receiving dolutegravir were not affected, while eGFRcr was significantly higher in those receiving dolutegravir</td>
</tr>
<tr>
<td align="left" valign="top">Monin et al. (<xref ref-type="bibr" rid="ref49">49</xref>)</td>
<td align="left" valign="top">Germany</td>
<td align="left" valign="top">Randomized controlled trial</td>
<td align="left" valign="top">PLWH (<italic>n</italic> =&#x2009;263) on ART, with a mean age of 17&#x2009;years</td>
<td align="left" valign="top">Switched to dolutegravir + boosted darunavir (with ritonavir) or continued with two nucleoside reverse transcriptase inhibitors in combination with ritonavir-boosted darunavir once daily for 48&#x2009;weeks</td>
<td align="left" valign="top">eGFRscr was reduced while serum levels of cystatin C were not affected. Meanwhile, the low-density lipoprotein fraction was improved</td>
</tr>
<tr>
<td align="left" valign="top">Mondesert et al. (<xref ref-type="bibr" rid="ref23">23</xref>)</td>
<td align="left" valign="top">France</td>
<td align="left" valign="top">Observational study</td>
<td align="left" valign="top">PLWH on ART (<italic>n</italic> =&#x2009;262) with kidney dysfunction</td>
<td align="left" valign="top">Received cobicistat +elvitegravir, ritonavir + protease inhibitor, dolutegravir, dolutegravir +rilpivirine, rilpivirine, raltegravir, bictegravir, and other antiretroviral drugs</td>
<td align="left" valign="top">Mean eGFR<sub>cystC</sub> was higher than mean eGFRscr</td>
</tr>
<tr>
<td align="left" valign="top">Rostania et al. (<xref ref-type="bibr" rid="ref50">50</xref>)</td>
<td align="left" valign="top">Indonesia</td>
<td align="left" valign="top">Cross-sectional study</td>
<td align="left" valign="top">PLWH (<italic>n</italic> =&#x2009;60) on ART PLWH with a mean age of 12&#x2009;years</td>
<td align="left" valign="top">Received a combination of tenofovir, stavudine, lamivudine, zidovudine, abacavir, nevirapine, efavirenz, lopinavir/ for 8&#x2009;years, at least</td>
<td align="left" valign="top">The serum cystatin C levels were high and correlated with high viral load in PLWH on ART. However, CD4<sup>+</sup> count had no association with the serum levels of cystatin C</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec sec-type="discussion" id="sec8">
<label>4</label>
<title>Discussion</title>
<sec id="sec9">
<label>4.1</label>
<title>Clinical evidence on the potential use of cystatin C to monitor kidney disease in PLWH on ART</title>
<p>Approximately nine studies reported on the use of cystatin C, together with the creatinine-based GFR, to monitor the kidney function in PLWH on ART (<xref ref-type="table" rid="tab1">Table 1</xref>). However, nearly half of the studies included in this study supported the use of estimated GFR (from creatinine) as the preferred biomarker to assess or monitor the kidney function in PLWH on ART (<xref ref-type="bibr" rid="ref42">42</xref>, <xref ref-type="bibr" rid="ref45">45</xref>, <xref ref-type="bibr" rid="ref46">46</xref>, <xref ref-type="bibr" rid="ref49">49</xref>). Interestingly, in addition to using GFR-based creatinine to monitor kidney disease, most of these studies favored the use of additional biomarkers to assess the kidney function in PLWH (<xref ref-type="table" rid="tab1">Table 1</xref>). These biomarkers include albuminuria, proteinuria, and renal phosphate or urea handling, although cystatin C was predominantly used (<xref ref-type="table" rid="tab1">Table 1</xref>). In terms of reliability between both creatinine- and cystatin-based GFRs, it was evident that the reported information was inconsistent between the studied subjects. For example, in some studies, it was shown that while the creatinine-based GFR was fluctuating, the levels of cystatin C remained unchanged and could be reliably used to monitor the kidney function in PLWH (<xref ref-type="bibr" rid="ref24">24</xref>, <xref ref-type="bibr" rid="ref49">49</xref>), while other studies indicated that using both creatinine- and cystatin C-based GFRs could even be more reliable than using either marker alone in monitoring the kidney function in PLWH (<xref ref-type="bibr" rid="ref36">36</xref>, <xref ref-type="bibr" rid="ref43">43</xref>, <xref ref-type="bibr" rid="ref46">46</xref>). Nonetheless, other studies indicated that cystatin C use alone could also be effectively used to detect the kidney function or kidney disease in PLWH (<xref ref-type="bibr" rid="ref45">45</xref>), even correlating cystatin C levels with high viral loads in some participants (<xref ref-type="bibr" rid="ref50">50</xref>). In other studies (<xref ref-type="bibr" rid="ref34">34</xref>, <xref ref-type="bibr" rid="ref35">35</xref>, <xref ref-type="bibr" rid="ref40">40</xref>), it was also evident that elevated levels of cystatin C were consistent with increased levels of pro-inflammatory markers such as C-reactive protein, leptin, and interleukin-6/&#x2212;18, possibly indicating other underlying conditions such as metabolic disease, which could contribute to the progression of kidney dysfunction in PLWH. Interestingly, in recent years, the rapid growth in the prevalence of metabolic diseases that is accompanied by abnormally high levels of inflammation has significantly affected PLWH (<xref ref-type="bibr" rid="ref51 ref52 ref53 ref54">51&#x2013;54</xref>), possibly contributing to the high burden of disease in many developing and developed countries.</p>
</sec>
<sec id="sec10">
<label>4.2</label>
<title>Impact of ART on serum levels of cystatin C and other biomarkers of kidney disease in PLWH</title>
<p>It is important to note that the initial use of the zidovudine drug, which was approved in 1987 by the United States Food and Drug Administration, was instrumental in initiating the effective management of PLWH (<xref ref-type="bibr" rid="ref55">55</xref>). Currently, many developments have been made in terms of managing PLWH, especially through the use of ART to suppress or reduce the viral load (<xref ref-type="bibr" rid="ref56">56</xref>). In fact, the published literature predominately reports on recent ART combinations, especially protease inhibitors or nucleoside reverse transcriptase inhibitors, which are potentially linked with the development of non-communicable diseases, including kidney disease-associated risk factors (<xref ref-type="bibr" rid="ref57 ref58 ref59">57&#x2013;59</xref>). Notably, the sustained use of a tenofovir disoproxil fumarate-containing ART regimen has been linked with the detrimental effects of oxidative stress and inflammation, driving pathological abnormalities in renal cells (<xref ref-type="bibr" rid="ref60">60</xref>, <xref ref-type="bibr" rid="ref61">61</xref>). This could be observed independently through the fluctuations in cystatin C levels in PLWH on ART (<xref ref-type="bibr" rid="ref41">41</xref>). However, it was evident that the effective use of ART and suppression of CD4+ cell count were associated with low cystatin C levels in some patients (<xref ref-type="bibr" rid="ref32">32</xref>, <xref ref-type="bibr" rid="ref33">33</xref>, <xref ref-type="bibr" rid="ref41">41</xref>). Thus, it remains important to understand the relationship between serum cystatin C and eGFR to monitor the kidney function in PLWH on ART. In this study, evidence indicated that the creatinine-based GFR increased in PLWH taking tenofovir disoproxil fumarate-containing ART (<xref ref-type="bibr" rid="ref42">42</xref>, <xref ref-type="bibr" rid="ref45">45</xref>), but this was not observed in other studies (<xref ref-type="bibr" rid="ref46">46</xref>, <xref ref-type="bibr" rid="ref48">48</xref>). Moreover, switching to a dolutegravir-based ART regimen could improve the kidney function in PLWH, as measured using both creatinine- and cystatin C-based GFRs (<xref ref-type="table" rid="tab1">Table 1</xref>).</p>
</sec>
<sec id="sec11">
<label>4.3</label>
<title>Summary and future perspective</title>
<p>Kidney injury is common in PLWH and has been associated with an increased risk of morbidity and mortality (<xref ref-type="bibr" rid="ref62">62</xref>). Therefore, it has become imperative to routinely monitor biomarkers of kidney disease in PLWH. This aspect affirms existing literature on the necessity for screening, early diagnosis, and prediction of kidney disease in PLWH, especially those from low- and middle-income countries (<xref ref-type="bibr" rid="ref63">63</xref>, <xref ref-type="bibr" rid="ref64">64</xref>). Although serum creatinine is considered an indirect marker for the renal GFR, it lacks specificity to detect damage to kidney tissue, and its relatively delayed response to injury could hinder early detection of acute kidney injury (<xref ref-type="bibr" rid="ref65">65</xref>). Furthermore, studies have reported that serum creatinine levels are elevated with increasing age, body weight, and grip strength in some PLWH (<xref ref-type="bibr" rid="ref66">66</xref>). This information renders this biomarker potentially unreliable to efficiently monitor the kidney function or the development of kidney disease. Clinical evidence from the current review indicates that while the measurement of creatinine-based GFR can fluctuate, cystatin C is likely to remain consistent in PLWH on ART. The use of both creatinine- and cystatin C-based GRF remains important and is recommended for monitoring the kidney function in PLWH on ART. However, the costs associated with the routine use of cystatin C together with creatinine to monitor the kidney function should be considered. In terms of the type of ART regimen, the use of tenofovir-containing ART may be potentially detrimental by increasing creatinine-based GFR as an indicator of kidney dysfunction in PLWH, while that of dolutegravir-based ART could be less toxic to the kidney. Evidence already supports the beneficial or superior effects of dolutegravir in combination with nucleoside reverse transcriptase inhibitors for suppressing HIV in PLWH (<xref ref-type="bibr" rid="ref67">67</xref>, <xref ref-type="bibr" rid="ref68">68</xref>). This aspect underscores the need for more evidence to confirm these effects, especially since the cystatin C-based GFR was not affected. Further research is still required to provide a clear description of the modulation of these biomarkers to describe the relationship between both acute and chronic kidney dysfunction in PLWH on ART. Importantly, additional clinical evidence is required to determine the impact of different ART regimens on kidney injury in PLWH.</p>
</sec>
</sec>
<sec sec-type="data-availability" id="sec12">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1">Supplementary material</xref>, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="author-contributions" id="sec13">
<title>Author contributions</title>
<p>SH: Conceptualization, Funding acquisition, Investigation, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. JC: Conceptualization, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. HM: Writing &#x2013; review &#x0026; editing. SM: Funding acquisition, Writing &#x2013; review &#x0026; editing. ZM: Writing &#x2013; review &#x0026; editing. MM: Writing &#x2013; review &#x0026; editing, Data curation. NM: Writing &#x2013; review &#x0026; editing, Data curation. BN: Writing &#x2013; review &#x0026; editing. DN: Writing &#x2013; review &#x0026; editing. UN: Writing &#x2013; review &#x0026; editing. AK: Writing &#x2013; review &#x0026; editing. PD: Conceptualization, Funding acquisition, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing, Methodology, Supervision.</p>
</sec>
</body>
<back>
<sec sec-type="funding-information" id="sec14">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. SH was funded by the National Research Foundation (NRF) (grant number: TTK2204082828). PD was supported in part by the NRF (grant numbers: 117829 and 141929). The study by SM, reported herein, was made possible through partial funding by the South African Medical Research Council through its Division of Research Capacity Development under the Researcher Development Award Program. NM acknowledges funding from the NRF.</p>
</sec>
<sec sec-type="COI-statement" id="sec15">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="sec100" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="disclaimer" id="sec16">
<title>Author disclaimer</title>
<p>The content hereof is the sole responsibility of the authors and does not necessarily represent the official views of the NRF.</p>
</sec>
<sec sec-type="supplementary-material" id="sec17">
<title>Supplementary material</title>
<p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fmed.2024.1295217/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fmed.2024.1295217/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Data_Sheet_1.pdf" id="SM1" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Data_Sheet_2.docx" id="SM2" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Data_Sheet_3.pdf" id="SM3" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Data_Sheet_4.xlsx" id="SM4" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<fn-group>
<title>Abbreviations</title>
<fn fn-type="abbr"><p>ART, Antiretroviral therapy; HIV, Human immunodeficiency virus; LDL, Low-density lipoprotein; PECO, Population, Exposure, Comparison, Outcome; PLWH, People living with human immunodeficiency virus; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PROSPERO, International Prospective Register for Systematic Reviews.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kovesdy</surname> <given-names>CP</given-names></name></person-group>. <article-title>Epidemiology of chronic kidney disease: an update 2022</article-title>. <source>Kidney Int Suppl</source>. (<year>2022</year>) <volume>12</volume>:<fpage>7</fpage>&#x2013;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.kisu.2021.11.003</pub-id></citation></ref>
<ref id="ref2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hariparshad</surname> <given-names>S</given-names></name> <name><surname>Bhimma</surname> <given-names>R</given-names></name> <name><surname>Nandlal</surname> <given-names>L</given-names></name> <name><surname>Jembere</surname> <given-names>E</given-names></name> <name><surname>Naicker</surname> <given-names>S</given-names></name> <name><surname>Assounga</surname> <given-names>A</given-names></name></person-group>. <article-title>The prevalence of chronic kidney disease in South Africa&#x2014;limitations of studies comparing prevalence with sub-Saharan Africa, Africa, and globally</article-title>. <source>BMC Nephrol</source>. (<year>2023</year>) <volume>24</volume>:<fpage>62</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12882-023-03109-1</pub-id>, PMID: <pub-id pub-id-type="pmid">36944928</pub-id></citation></ref>
<ref id="ref3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alfano</surname> <given-names>G</given-names></name> <name><surname>Cappelli</surname> <given-names>G</given-names></name> <name><surname>Fontana</surname> <given-names>F</given-names></name> <name><surname>di Lullo</surname> <given-names>L</given-names></name> <name><surname>di Iorio</surname> <given-names>B</given-names></name> <name><surname>Bellasi</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>Kidney disease in HIV infection</article-title>. <source>J Clin Med</source>. (<year>2019</year>) <volume>8</volume>:<fpage>1254</fpage>. doi: <pub-id pub-id-type="doi">10.3390/jcm8081254</pub-id>, PMID: <pub-id pub-id-type="pmid">31430930</pub-id></citation></ref>
<ref id="ref4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferenbach</surname> <given-names>DA</given-names></name> <name><surname>Bonventre</surname> <given-names>JV</given-names></name></person-group>. <article-title>Acute kidney injury and chronic kidney disease: from the laboratory to the clinic</article-title>. <source>Nephrol Ther</source>. (<year>2016</year>) <volume>12</volume>:<fpage>S41</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nephro.2016.02.005</pub-id></citation></ref>
<ref id="ref5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Makris</surname> <given-names>K</given-names></name> <name><surname>Spanou</surname> <given-names>L</given-names></name></person-group>. <article-title>Acute kidney injury: definition, pathophysiology and clinical phenotypes</article-title>. <source>Clin Biochem Rev</source>. (<year>2016</year>) <volume>37</volume>:<fpage>85</fpage>&#x2013;<lpage>98</lpage>. PMID: <pub-id pub-id-type="pmid">28303073</pub-id></citation></ref>
<ref id="ref6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname> <given-names>MC</given-names></name> <name><surname>Fazzari</surname> <given-names>MJ</given-names></name> <name><surname>Hanna</surname> <given-names>DB</given-names></name> <name><surname>Patel</surname> <given-names>VV</given-names></name> <name><surname>Felsen</surname> <given-names>UR</given-names></name> <name><surname>Alahiri</surname> <given-names>E</given-names></name> <etal/></person-group>. <article-title>Brief report: acute kidney injury in people living with HIV hospitalized with coronavirus disease 2019: clinical characteristics and outcomes</article-title>. <source>J Acquir Immune Defic Syndr</source>. (<year>2021</year>) <volume>87</volume>:<fpage>1167</fpage>&#x2013;<lpage>72</lpage>. doi: <pub-id pub-id-type="doi">10.1097/QAI.0000000000002698</pub-id>, PMID: <pub-id pub-id-type="pmid">34229329</pub-id></citation></ref>
<ref id="ref7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Y</given-names></name> <name><surname>Shlipak</surname> <given-names>MG</given-names></name> <name><surname>Grunfeld</surname> <given-names>C</given-names></name> <name><surname>Choi</surname> <given-names>AI</given-names></name></person-group>. <article-title>Incidence and risk factors for acute kidney injury in HIV infection</article-title>. <source>Am J Nephrol</source>. (<year>2012</year>) <volume>35</volume>:<fpage>327</fpage>&#x2013;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000337151</pub-id>, PMID: <pub-id pub-id-type="pmid">22456100</pub-id></citation></ref>
<ref id="ref8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>George</surname> <given-names>C</given-names></name> <name><surname>Hill</surname> <given-names>J</given-names></name> <name><surname>Nqebelele</surname> <given-names>U</given-names></name> <name><surname>Peer</surname> <given-names>N</given-names></name> <name><surname>Kengne</surname> <given-names>AP</given-names></name></person-group>. <article-title>Leveraging the south African diabetes prevention Programme to screen for chronic kidney disease: an observational study</article-title>. <source>BMJ Open</source>. (<year>2023</year>) <volume>13</volume>:<fpage>e068672</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmjopen-2022-068672</pub-id>, PMID: <pub-id pub-id-type="pmid">36609330</pub-id></citation></ref>
<ref id="ref9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Montessori</surname> <given-names>V</given-names></name> <name><surname>Press</surname> <given-names>N</given-names></name> <name><surname>Harris</surname> <given-names>M</given-names></name> <name><surname>Akagi</surname> <given-names>L</given-names></name> <name><surname>Montaner</surname> <given-names>JS</given-names></name></person-group>. <article-title>Adverse effects of antiretroviral therapy for HIV infection</article-title>. <source>CMAJ</source>. (<year>2004</year>) <volume>170</volume>:<fpage>229</fpage>&#x2013;<lpage>38</lpage>. PMID: <pub-id pub-id-type="pmid">14734438</pub-id></citation></ref>
<ref id="ref10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname> <given-names>BF</given-names></name> <name><surname>Peixoto</surname> <given-names>G</given-names></name> <name><surname>da Luz</surname> <given-names>SR</given-names></name> <name><surname>de Moraes</surname> <given-names>S</given-names></name> <name><surname>Peres</surname> <given-names>SB</given-names></name></person-group>. <article-title>Adverse effects of chronic treatment with the Main subclasses of highly active antiretroviral therapy: a systematic review</article-title>. <source>HIV Med</source>. (<year>2019</year>) <volume>20</volume>:<fpage>429</fpage>&#x2013;<lpage>38</lpage>. doi: <pub-id pub-id-type="doi">10.1111/hiv.12733</pub-id></citation></ref>
<ref id="ref11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wyatt</surname> <given-names>CM</given-names></name></person-group>. <article-title>Kidney disease and HIV infection</article-title>. <source>Top Antivir Med</source>. (<year>2017</year>) <volume>25</volume>:<fpage>13</fpage>&#x2013;<lpage>6</lpage>.</citation></ref>
<ref id="ref12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kabor&#x00E9;</surname> <given-names>NF</given-names></name> <name><surname>Poda</surname> <given-names>A</given-names></name> <name><surname>Zoungrana</surname> <given-names>J</given-names></name> <name><surname>da</surname> <given-names>O</given-names></name> <name><surname>Ciaffi</surname> <given-names>L</given-names></name> <name><surname>Semd&#x00E9;</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting</article-title>. <source>BMC Nephrol</source>. (<year>2019</year>) <volume>20</volume>:<fpage>155</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12882-019-1335-9</pub-id></citation></ref>
<ref id="ref13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Swanepoel</surname> <given-names>CR</given-names></name> <name><surname>Atta</surname> <given-names>MG</given-names></name> <name><surname>D'Agati</surname> <given-names>VD</given-names></name> <name><surname>Estrella</surname> <given-names>MM</given-names></name> <name><surname>Fogo</surname> <given-names>AB</given-names></name> <name><surname>Naicker</surname> <given-names>S</given-names></name> <etal/></person-group>. <article-title>Kidney disease in the setting of HIV infection: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference</article-title>. <source>Kidney Int</source>. (<year>2018</year>) <volume>93</volume>:<fpage>545</fpage>&#x2013;<lpage>59</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.kint.2017.11.007</pub-id></citation></ref>
<ref id="ref14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oguntibeju</surname> <given-names>OO</given-names></name></person-group>. <article-title>Quality of life of people living with HIV and AIDS and antiretroviral therapy</article-title>. <source>HIV AIDS</source>. (<year>2012</year>) <volume>4</volume>:<fpage>117</fpage>&#x2013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.2147/HIV.S32321</pub-id>, PMID: <pub-id pub-id-type="pmid">22893751</pub-id></citation></ref>
<ref id="ref15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diana</surname> <given-names>NE</given-names></name> <name><surname>Davies</surname> <given-names>M</given-names></name> <name><surname>Mosiane</surname> <given-names>P</given-names></name> <name><surname>Vermeulen</surname> <given-names>A</given-names></name> <name><surname>Naicker</surname> <given-names>S</given-names></name></person-group>. <article-title>Clinicopathological correlation of kidney disease in HIV infection pre- and post-ART rollout</article-title>. <source>PLoS One</source>. (<year>2022</year>) <volume>17</volume>:<fpage>e0269260</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0269260</pub-id>, PMID: <pub-id pub-id-type="pmid">35639767</pub-id></citation></ref>
<ref id="ref16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname> <given-names>GM</given-names></name> <name><surname>Cozzi-Lepri</surname> <given-names>A</given-names></name> <name><surname>Wyatt</surname> <given-names>CM</given-names></name> <name><surname>Post</surname> <given-names>FA</given-names></name> <name><surname>Bormann</surname> <given-names>AM</given-names></name> <name><surname>Crum-Cianflone</surname> <given-names>NF</given-names></name> <etal/></person-group>. <article-title>Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals</article-title>. <source>HIV Med</source>. (<year>2014</year>) <volume>15</volume>:<fpage>116</fpage>&#x2013;<lpage>23</lpage>. doi: <pub-id pub-id-type="doi">10.1111/hiv.12087</pub-id>, PMID: <pub-id pub-id-type="pmid">24024499</pub-id></citation></ref>
<ref id="ref17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yukawa</surname> <given-names>S</given-names></name> <name><surname>Watanabe</surname> <given-names>D</given-names></name> <name><surname>Uehira</surname> <given-names>T</given-names></name> <name><surname>Shirasaka</surname> <given-names>T</given-names></name></person-group>. <article-title>Clinical benefits of using inulin clearance and cystatin C for determining glomerular filtration rate in HIV-1-infected individuals treated with dolutegravir</article-title>. <source>J Infect Chemother</source>. (<year>2018</year>) <volume>24</volume>:<fpage>199</fpage>&#x2013;<lpage>205</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jiac.2017.10.015</pub-id>, PMID: <pub-id pub-id-type="pmid">29150412</pub-id></citation></ref>
<ref id="ref18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heron</surname> <given-names>JE</given-names></name> <name><surname>Bagnis</surname> <given-names>CI</given-names></name> <name><surname>Gracey</surname> <given-names>DM</given-names></name></person-group>. <article-title>Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV</article-title>. <source>AIDS Res Ther</source>. (<year>2020</year>) <volume>17</volume>:<fpage>11</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12981-020-00266-3</pub-id>, PMID: <pub-id pub-id-type="pmid">32178687</pub-id></citation></ref>
<ref id="ref19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murty</surname> <given-names>MS</given-names></name> <name><surname>Sharma</surname> <given-names>UK</given-names></name> <name><surname>Pandey</surname> <given-names>VB</given-names></name> <name><surname>Kankare</surname> <given-names>SB</given-names></name></person-group>. <article-title>Serum cystatin C as a marker of renal function in detection of early acute kidney injury</article-title>. <source>Indian J Nephrol</source>. (<year>2013</year>) <volume>23</volume>:<fpage>180</fpage>&#x2013;<lpage>3</lpage>. doi: <pub-id pub-id-type="doi">10.4103/0971-4065.111840</pub-id></citation></ref>
<ref id="ref20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baxmann</surname> <given-names>AC</given-names></name> <name><surname>Ahmed</surname> <given-names>MS</given-names></name> <name><surname>Marques</surname> <given-names>NC</given-names></name> <name><surname>Menon</surname> <given-names>VB</given-names></name> <name><surname>Pereira</surname> <given-names>AB</given-names></name> <name><surname>Kirsztajn</surname> <given-names>GM</given-names></name> <etal/></person-group>. <article-title>Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C</article-title>. <source>Clin J Am Soc Nephrol</source>. (<year>2008</year>) <volume>3</volume>:<fpage>348</fpage>&#x2013;<lpage>54</lpage>. doi: <pub-id pub-id-type="doi">10.2215/CJN.02870707</pub-id>, PMID: <pub-id pub-id-type="pmid">18235143</pub-id></citation></ref>
<ref id="ref21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaitonde</surname> <given-names>DY</given-names></name> <name><surname>Cook</surname> <given-names>DL</given-names></name> <name><surname>Rivera</surname> <given-names>IM</given-names></name></person-group>. <article-title>Chronic kidney disease: detection and evaluation</article-title>. <source>Am Fam Physician</source>. (<year>2017</year>) <volume>96</volume>:<fpage>776</fpage>&#x2013;<lpage>83</lpage>.</citation></ref>
<ref id="ref22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname> <given-names>TW</given-names></name> <name><surname>Komenda</surname> <given-names>P</given-names></name> <name><surname>Tangri</surname> <given-names>N</given-names></name></person-group>. <article-title>Cystatin C as a biomarker for estimating glomerular filtration rate</article-title>. <source>Curr Opin Nephrol Hypertens</source>. (<year>2015</year>) <volume>24</volume>:<fpage>295</fpage>&#x2013;<lpage>300</lpage>. doi: <pub-id pub-id-type="doi">10.1097/MNH.0000000000000115</pub-id></citation></ref>
<ref id="ref23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mondesert</surname> <given-names>E</given-names></name> <name><surname>Reynes</surname> <given-names>J</given-names></name> <name><surname>Makinson</surname> <given-names>A</given-names></name> <name><surname>Bargnoux</surname> <given-names>AS</given-names></name> <name><surname>Plawecki</surname> <given-names>M</given-names></name> <name><surname>Morquin</surname> <given-names>D</given-names></name> <etal/></person-group>. <article-title>Cystatin C in addition to creatinine for better assessment of glomerular renal function decline in people with HIV receiving antiretroviral therapy</article-title>. <source>AIDS</source>. (<year>2023</year>) <volume>37</volume>:<fpage>447</fpage>&#x2013;<lpage>54</lpage>. doi: <pub-id pub-id-type="doi">10.1097/QAD.0000000000003434</pub-id>, PMID: <pub-id pub-id-type="pmid">36695357</pub-id></citation></ref>
<ref id="ref24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Casado</surname> <given-names>JL</given-names></name> <name><surname>Monsalvo</surname> <given-names>M</given-names></name> <name><surname>Vizcarra</surname> <given-names>P</given-names></name> <name><surname>Fontecha</surname> <given-names>M</given-names></name> <name><surname>Serrano-Villar</surname> <given-names>S</given-names></name> <name><surname>Moreno</surname> <given-names>S</given-names></name></person-group>. <article-title>Evaluation of kidney function in HIV-infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinine</article-title>. <source>HIV Med</source>. (<year>2019</year>) <volume>20</volume>:<fpage>648</fpage>&#x2013;<lpage>56</lpage>. doi: <pub-id pub-id-type="doi">10.1111/hiv.12784</pub-id></citation></ref>
<ref id="ref25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>DC</given-names></name> <name><surname>Lees</surname> <given-names>JS</given-names></name> <name><surname>Lu</surname> <given-names>K</given-names></name> <name><surname>Scherzer</surname> <given-names>R</given-names></name> <name><surname>Rutherford</surname> <given-names>E</given-names></name> <name><surname>Mark</surname> <given-names>PB</given-names></name> <etal/></person-group>. <article-title>Differential associations of cystatin C versus creatinine-based kidney function with risks of cardiovascular event and mortality among south Asian individuals in the UK biobank</article-title>. <source>J Am Heart Assoc</source>. (<year>2023</year>) <volume>12</volume>:<fpage>e027079</fpage>. doi: <pub-id pub-id-type="doi">10.1161/JAHA.122.027079</pub-id>, PMID: <pub-id pub-id-type="pmid">36695320</pub-id></citation></ref>
<ref id="ref26"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gagneux-Brunon</surname> <given-names>A</given-names></name> <name><surname>Mariat</surname> <given-names>C</given-names></name> <name><surname>Delanaye</surname> <given-names>P</given-names></name></person-group>. <article-title>Cystatin C in HIV-infected patients: promising but not yet ready for prime time</article-title>. <source>Nephrol Dial Transplant</source>. (<year>2012</year>) <volume>27</volume>:<fpage>1305</fpage>&#x2013;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1093/ndt/gfs001</pub-id></citation></ref>
<ref id="ref27"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wondifraw Baynes</surname> <given-names>H</given-names></name> <name><surname>Tegene</surname> <given-names>B</given-names></name> <name><surname>Gebremichael</surname> <given-names>M</given-names></name> <name><surname>Birhane</surname> <given-names>G</given-names></name> <name><surname>Kedir</surname> <given-names>W</given-names></name> <name><surname>Biadgo</surname> <given-names>B</given-names></name></person-group>. <article-title>Assessment of the effect of antiretroviral therapy on renal and liver functions among HIV-infected patients: a retrospective study</article-title>. <source>HIV AIDS</source>. (<year>2017</year>) <volume>9</volume>:<fpage>1</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.2147/HIV.S120979</pub-id>, PMID: <pub-id pub-id-type="pmid">28053556</pub-id></citation></ref>
<ref id="ref28"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>R&#x00F6;ling</surname> <given-names>J</given-names></name> <name><surname>Schmid</surname> <given-names>H</given-names></name> <name><surname>Fischereder</surname> <given-names>M</given-names></name> <name><surname>Draenert</surname> <given-names>R</given-names></name> <name><surname>Goebel</surname> <given-names>FD</given-names></name></person-group>. <article-title>HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy</article-title>. <source>Clin Infect Dis</source>. (<year>2006</year>) <volume>42</volume>:<fpage>1488</fpage>&#x2013;<lpage>95</lpage>. doi: <pub-id pub-id-type="doi">10.1086/503566</pub-id>, PMID: <pub-id pub-id-type="pmid">16619164</pub-id></citation></ref>
<ref id="ref29"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cumpston</surname> <given-names>M</given-names></name> <name><surname>Li</surname> <given-names>T</given-names></name> <name><surname>Page</surname> <given-names>MJ</given-names></name> <name><surname>Chandler</surname> <given-names>J</given-names></name> <name><surname>Welch</surname> <given-names>VA</given-names></name> <name><surname>Higgins</surname> <given-names>JPT</given-names></name> <etal/></person-group>. <article-title>Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions</article-title>. <source>Cochrane Database Syst Rev</source>. (<year>2019</year>) <volume>10</volume>:<fpage>Ed000142</fpage>. doi: <pub-id pub-id-type="doi">10.1002/14651858.ED000142</pub-id></citation></ref>
<ref id="ref30"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Downs</surname> <given-names>SH</given-names></name> <name><surname>Black</surname> <given-names>N</given-names></name></person-group>. <article-title>The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions</article-title>. <source>J Epidemiol Community Health</source>. (<year>1998</year>) <volume>52</volume>:<fpage>377</fpage>&#x2013;<lpage>84</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jech.52.6.377</pub-id>, PMID: <pub-id pub-id-type="pmid">9764259</pub-id></citation></ref>
<ref id="ref31"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Connor</surname> <given-names>SR</given-names></name> <name><surname>Tully</surname> <given-names>MA</given-names></name> <name><surname>Ryan</surname> <given-names>B</given-names></name> <name><surname>Bradley</surname> <given-names>JM</given-names></name> <name><surname>Baxter</surname> <given-names>GD</given-names></name> <name><surname>McDonough</surname> <given-names>SM</given-names></name></person-group>. <article-title>Failure of a numerical quality assessment scale to identify potential risk of bias in a systematic review: a comparison study</article-title>. <source>BMC Res Notes</source>. (<year>2015</year>) <volume>8</volume>:<fpage>224</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13104-015-1181-1</pub-id>, PMID: <pub-id pub-id-type="pmid">26048813</pub-id></citation></ref>
<ref id="ref32"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname> <given-names>CY</given-names></name> <name><surname>Jones</surname> <given-names>CA</given-names></name> <name><surname>Wilson</surname> <given-names>IB</given-names></name> <name><surname>Knox</surname> <given-names>TA</given-names></name> <name><surname>Levey</surname> <given-names>AS</given-names></name> <name><surname>Spiegelman</surname> <given-names>D</given-names></name> <etal/></person-group>. <article-title>Cystatin C and creatinine in an HIV cohort: the nutrition for healthy living study</article-title>. <source>Am J Kidney Dis</source>. (<year>2008</year>) <volume>51</volume>:<fpage>914</fpage>&#x2013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.1053/j.ajkd.2008.01.027</pub-id>, PMID: <pub-id pub-id-type="pmid">18455851</pub-id></citation></ref>
<ref id="ref33"><label>33.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mauss</surname> <given-names>S</given-names></name> <name><surname>Berger</surname> <given-names>F</given-names></name> <name><surname>Kuschak</surname> <given-names>D</given-names></name> <name><surname>Henke</surname> <given-names>J</given-names></name> <name><surname>Hegener</surname> <given-names>P</given-names></name> <name><surname>Wolf</surname> <given-names>E</given-names></name> <etal/></person-group>. <article-title>Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients</article-title>. <source>Antivir Ther</source>. (<year>2008</year>) <volume>13</volume>:<fpage>1091</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1177/135965350801300810</pub-id>, PMID: <pub-id pub-id-type="pmid">19195336</pub-id></citation></ref>
<ref id="ref34"><label>34.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Falasca</surname> <given-names>K</given-names></name> <name><surname>Ucciferri</surname> <given-names>C</given-names></name> <name><surname>Mancino</surname> <given-names>P</given-names></name> <name><surname>di Iorio</surname> <given-names>A</given-names></name> <name><surname>Vignale</surname> <given-names>F</given-names></name> <name><surname>Pizzigallo</surname> <given-names>E</given-names></name> <etal/></person-group>. <article-title>Cystatin C, adipokines and cardiovascular risk in HIV infected patients</article-title>. <source>Curr HIV Res</source>. (<year>2010</year>) <volume>8</volume>:<fpage>405</fpage>&#x2013;<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.2174/157016210791330365</pub-id>, PMID: <pub-id pub-id-type="pmid">20426756</pub-id></citation></ref>
<ref id="ref35"><label>35.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Falasca</surname> <given-names>K</given-names></name> <name><surname>Ucciferri</surname> <given-names>C</given-names></name> <name><surname>Mancino</surname> <given-names>P</given-names></name> <name><surname>Vignale</surname> <given-names>F</given-names></name> <name><surname>Vecchiet</surname> <given-names>J</given-names></name></person-group>. <article-title>Cystatin C and cardiovascular risk in HIV infected patients</article-title>. <source>Retrovirology</source>. (<year>2010</year>) <volume>7</volume>:<fpage>P62</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1742-4690-7-S1-P62</pub-id></citation></ref>
<ref id="ref36"><label>36.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inker</surname> <given-names>LA</given-names></name> <name><surname>Wyatt</surname> <given-names>C</given-names></name> <name><surname>Creamer</surname> <given-names>R</given-names></name> <name><surname>Hellinger</surname> <given-names>J</given-names></name> <name><surname>Hotta</surname> <given-names>M</given-names></name> <name><surname>Leppo</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals</article-title>. <source>J Acquir Immune Defic Syndr</source>. (<year>2012</year>) <volume>61</volume>:<fpage>302</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1097/QAI.0b013e31826a6c4f</pub-id>, PMID: <pub-id pub-id-type="pmid">22842844</pub-id></citation></ref>
<ref id="ref37"><label>37.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Overton</surname> <given-names>ET</given-names></name> <name><surname>Patel</surname> <given-names>P</given-names></name> <name><surname>Mondy</surname> <given-names>K</given-names></name> <name><surname>Bush</surname> <given-names>T</given-names></name> <name><surname>Conley</surname> <given-names>L</given-names></name> <name><surname>Rhame</surname> <given-names>F</given-names></name> <etal/></person-group>. <article-title>Cystatin C and baseline renal function among HIV-infected persons in the SUN study</article-title>. <source>AIDS Res Hum Retrovir</source>. (<year>2012</year>) <volume>28</volume>:<fpage>148</fpage>&#x2013;<lpage>55</lpage>. doi: <pub-id pub-id-type="doi">10.1089/aid.2011.0018</pub-id>, PMID: <pub-id pub-id-type="pmid">21480819</pub-id></citation></ref>
<ref id="ref38"><label>38.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bhasin</surname> <given-names>B</given-names></name> <name><surname>Lau</surname> <given-names>B</given-names></name> <name><surname>Atta</surname> <given-names>MG</given-names></name> <name><surname>Fine</surname> <given-names>DM</given-names></name> <name><surname>Estrella</surname> <given-names>MM</given-names></name> <name><surname>Schwartz</surname> <given-names>GJ</given-names></name> <etal/></person-group>. <article-title>HIV viremia and T-cell activation differentially affect the performance of glomerular filtration rate equations based on creatinine and cystatin C</article-title>. <source>PLoS One</source>. (<year>2013</year>) <volume>8</volume>:<fpage>e82028</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0082028</pub-id>, PMID: <pub-id pub-id-type="pmid">24376511</pub-id></citation></ref>
<ref id="ref39"><label>39.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoshino</surname> <given-names>Y</given-names></name> <name><surname>Koga</surname> <given-names>I</given-names></name> <name><surname>Seo</surname> <given-names>K</given-names></name> <name><surname>Kitazawa</surname> <given-names>T</given-names></name> <name><surname>Ota</surname> <given-names>Y</given-names></name></person-group>. <article-title>Short communication: the clinical value of cystatin C as a marker of renal function in HIV patients receiving Dolutegravir</article-title>. <source>AIDS Res Hum Retrovir</source>. (<year>2017</year>) <volume>33</volume>:<fpage>1080</fpage>&#x2013;<lpage>2</lpage>. doi: <pub-id pub-id-type="doi">10.1089/aid.2017.0074</pub-id>, PMID: <pub-id pub-id-type="pmid">28649847</pub-id></citation></ref>
<ref id="ref40"><label>40.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dragovi&#x0107;</surname> <given-names>G</given-names></name> <name><surname>Srdi&#x0107;</surname> <given-names>D</given-names></name> <name><surname>al Musalhi</surname> <given-names>K</given-names></name> <name><surname>Soldatovi&#x0107;</surname> <given-names>I</given-names></name> <name><surname>Ku&#x0161;i&#x0107;</surname> <given-names>J</given-names></name> <name><surname>Jevtovi&#x0107;</surname> <given-names>D</given-names></name> <etal/></person-group>. <article-title>Higher levels of cystatin C in HIV/AIDS patients with metabolic syndrome</article-title>. <source>Basic Clin Pharmacol Toxicol</source>. (<year>2018</year>) <volume>122</volume>:<fpage>396</fpage>&#x2013;<lpage>401</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bcpt.12919</pub-id>, PMID: <pub-id pub-id-type="pmid">29024496</pub-id></citation></ref>
<ref id="ref41"><label>41.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szymczak</surname> <given-names>A</given-names></name> <name><surname>Szymanek-Pasternak</surname> <given-names>A</given-names></name> <name><surname>Zalewska</surname> <given-names>M</given-names></name> <name><surname>Ma&#x0142;yszczak</surname> <given-names>K</given-names></name> <name><surname>Rymer</surname> <given-names>W</given-names></name> <name><surname>Knysz</surname> <given-names>B</given-names></name></person-group>. <article-title>Assessment of urinary cystatin C levels in HIV-1-infected patients with preserved kidney function</article-title>. <source>HIV AIDS Rev</source>. (<year>2018</year>) <volume>17</volume>:<fpage>236</fpage>&#x2013;<lpage>42</lpage>. doi: <pub-id pub-id-type="doi">10.5114/hivar.2018.80254</pub-id></citation></ref>
<ref id="ref42"><label>42.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamzah</surname> <given-names>L</given-names></name> <name><surname>Williams</surname> <given-names>D</given-names></name> <name><surname>Bailey</surname> <given-names>AC</given-names></name> <name><surname>Jones</surname> <given-names>R</given-names></name> <name><surname>Ibrahim</surname> <given-names>F</given-names></name> <name><surname>Musso</surname> <given-names>CG</given-names></name> <etal/></person-group>. <article-title>Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial</article-title>. <source>HIV Med</source>. (<year>2020</year>) <volume>21</volume>:<fpage>198</fpage>&#x2013;<lpage>203</lpage>. doi: <pub-id pub-id-type="doi">10.1111/hiv.12819</pub-id>, PMID: <pub-id pub-id-type="pmid">31679186</pub-id></citation></ref>
<ref id="ref43"><label>43.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ikpeama Osita John</surname> <given-names>OPA</given-names></name> <name><surname>Mariam</surname> <given-names>ON</given-names></name> <name><surname>Anthonia</surname> <given-names>IC</given-names></name> <name><surname>Joy</surname> <given-names>IC</given-names></name> <name><surname>Osazuwa</surname> <given-names>IO</given-names></name> <name><surname>Andrew</surname> <given-names>IE</given-names></name> <etal/></person-group>. <article-title>Study of cystatin C in early detection of renal impairment in patient with HIV/AIDS</article-title>. <source>South Asian Res J Agri Fisher</source>. (<year>2020</year>) <volume>2</volume>:<fpage>3</fpage>. doi: <pub-id pub-id-type="doi">10.36346/sarjaf.2020.v02i04.003</pub-id></citation></ref>
<ref id="ref44"><label>44.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ezeugwunne Ifeoma Priscilla</surname> <given-names>AC</given-names></name> <name><surname>Chukwuemeka</surname> <given-names>MS</given-names></name> <name><surname>Adamma</surname> <given-names>AR</given-names></name> <name><surname>Chinonso</surname> <given-names>NJ</given-names></name> <name><surname>Nwabunwanne</surname> <given-names>OV</given-names></name> <name><surname>Onyeka</surname> <given-names>IEC</given-names></name> <etal/></person-group>. <article-title>Evaluation of microalbumin, cystatin c, creatinine and uric acid levels in HIV patients in Nnamdi Azikiwe university teaching hospital, Nnewi</article-title>. <source>J Commun Health Manage</source>. (<year>2021</year>) <volume>8</volume>:<fpage>132</fpage>&#x2013;<lpage>42</lpage>. doi: <pub-id pub-id-type="doi">10.18231/j.jchm.2021.030</pub-id></citation></ref>
<ref id="ref45"><label>45.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rashbaum</surname> <given-names>B</given-names></name> <name><surname>Spinner</surname> <given-names>CD</given-names></name> <name><surname>McDonald</surname> <given-names>C</given-names></name> <name><surname>Mussini</surname> <given-names>C</given-names></name> <name><surname>Jezorwski</surname> <given-names>J</given-names></name> <name><surname>Luo</surname> <given-names>D</given-names></name> <etal/></person-group>. <article-title>Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-na&#x00EF;ve patients with HIV-1: subgroup analyses of the phase 3 AMBER study</article-title>. <source>HIV Res Clin Pract</source>. (<year>2019</year>) <volume>20</volume>:<fpage>24</fpage>&#x2013;<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.1080/15284336.2019.1608714</pub-id>, PMID: <pub-id pub-id-type="pmid">31303147</pub-id></citation></ref>
<ref id="ref46"><label>46.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>N</given-names></name> <name><surname>Zeng</surname> <given-names>Z</given-names></name> <name><surname>Liang</surname> <given-names>H</given-names></name> <name><surname>Wang</surname> <given-names>F</given-names></name> <name><surname>Yang</surname> <given-names>D</given-names></name> <name><surname>Xiao</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>Estimation of renal function by three CKD-EPI equations in Chinese HIV/AIDS patients: a STROBE-compliant article</article-title>. <source>Medicine</source>. (<year>2021</year>) <volume>100</volume>:<fpage>e26003</fpage>. doi: <pub-id pub-id-type="doi">10.1097/MD.0000000000026003</pub-id>, PMID: <pub-id pub-id-type="pmid">34087846</pub-id></citation></ref>
<ref id="ref47"><label>47.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hikasa</surname> <given-names>S</given-names></name> <name><surname>Shimabukuro</surname> <given-names>S</given-names></name> <name><surname>Hideta</surname> <given-names>K</given-names></name> <name><surname>Higasa</surname> <given-names>S</given-names></name> <name><surname>Sawada</surname> <given-names>A</given-names></name> <name><surname>Tokugawa</surname> <given-names>T</given-names></name> <etal/></person-group>. <article-title>Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on estimated glomerular filtration rate slope in patients with HIV: a retrospective observational study</article-title>. <source>J Infect Chemother</source>. (<year>2022</year>) <volume>28</volume>:<fpage>396</fpage>&#x2013;<lpage>400</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jiac.2021.11.016</pub-id></citation></ref>
<ref id="ref48"><label>48.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>L</given-names></name> <name><surname>Li</surname> <given-names>X</given-names></name> <name><surname>Liu</surname> <given-names>X</given-names></name> <name><surname>Han</surname> <given-names>Y</given-names></name> <name><surname>Qiu</surname> <given-names>Z</given-names></name> <name><surname>Song</surname> <given-names>X</given-names></name> <etal/></person-group>. <article-title>Comparison of renal function biomarkers of serum creatinine and cystatin C in HIV-infected people on Dolutegravir-containing therapy</article-title>. <source>Infect Drug Resist</source>. (<year>2022</year>) <volume>15</volume>:<fpage>1695</fpage>&#x2013;<lpage>706</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IDR.S347054</pub-id>, PMID: <pub-id pub-id-type="pmid">35422637</pub-id></citation></ref>
<ref id="ref49"><label>49.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Monin</surname> <given-names>M</given-names></name> <name><surname>K&#x00FC;mmerle</surname> <given-names>T</given-names></name> <name><surname>Schneider</surname> <given-names>J</given-names></name> <name><surname>Cordes</surname> <given-names>C</given-names></name> <name><surname>Heiken</surname> <given-names>H</given-names></name> <name><surname>Stellbrink</surname> <given-names>HJ</given-names></name> <etal/></person-group>. <article-title>Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes</article-title>. <source>HIV Res Clin Pract</source>. (<year>2021</year>) <volume>23</volume>:<fpage>15</fpage>&#x2013;<lpage>21</lpage>. PMID: <pub-id pub-id-type="pmid">35234092</pub-id></citation></ref>
<ref id="ref50"><label>50.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wita Rostania</surname> <given-names>AA</given-names></name> <name><surname>Hilmanto</surname> <given-names>D</given-names></name></person-group>. <article-title>Association of CD4 cell counts and viral load with cystatin C level in children with human immunodeficiency virus (HIV) infection</article-title>. <source>Paediatr Indones</source>. (<year>2023</year>) <volume>63</volume>:<fpage>88</fpage>&#x2013;<lpage>95</lpage>. doi: <pub-id pub-id-type="doi">10.14238/pi63.2.2023.88-95</pub-id></citation></ref>
<ref id="ref51"><label>51.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Todowede</surname> <given-names>OO</given-names></name> <name><surname>Mianda</surname> <given-names>SZ</given-names></name> <name><surname>Sartorius</surname> <given-names>B</given-names></name></person-group>. <article-title>Prevalence of metabolic syndrome among HIV-positive and HIV-negative populations in sub-Saharan Africa-a systematic review and meta-analysis</article-title>. <source>Syst Rev</source>. (<year>2019</year>) <volume>8</volume>:<fpage>4</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13643-018-0927-y</pub-id>, PMID: <pub-id pub-id-type="pmid">30606249</pub-id></citation></ref>
<ref id="ref52"><label>52.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ojong</surname> <given-names>E</given-names></name> <name><surname>Iya</surname> <given-names>B</given-names></name> <name><surname>Djeufouata</surname> <given-names>J</given-names></name> <name><surname>Ndeh</surname> <given-names>F</given-names></name> <name><surname>Nsonwu</surname> <given-names>A</given-names></name> <name><surname>Njongang</surname> <given-names>V</given-names></name> <etal/></person-group>. <article-title>Metabolic syndrome and its components among HIV/AIDS patients on antiretroviral therapy and ART-Na&#x00EF;ve patients at the University of Calabar Teaching Hospital, Calabar, Nigeria</article-title>. <source>Afr Health Sci</source>. (<year>2022</year>) <volume>22</volume>:<fpage>410</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.4314/ahs.v22i1.50</pub-id>, PMID: <pub-id pub-id-type="pmid">36032434</pub-id></citation></ref>
<ref id="ref53"><label>53.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nyambuya</surname> <given-names>TM</given-names></name> <name><surname>Dludla</surname> <given-names>PV</given-names></name> <name><surname>Mxinwa</surname> <given-names>V</given-names></name> <name><surname>Nkambule</surname> <given-names>BB</given-names></name></person-group>. <article-title>The effect of successful antiretroviral therapy on immune activation and reconstitution in HIV infected adults: a systematic review and Meta-analysis</article-title>. <source>AIDS Rev</source>. (<year>2020</year>) <volume>23</volume>:<fpage>1</fpage>&#x2013;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.24875/AIDSRev.20000039</pub-id>, PMID: <pub-id pub-id-type="pmid">33105472</pub-id></citation></ref>
<ref id="ref54"><label>54.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nkambule</surname> <given-names>BB</given-names></name> <name><surname>Mxinwa</surname> <given-names>V</given-names></name> <name><surname>Mkandla</surname> <given-names>Z</given-names></name> <name><surname>Mutize</surname> <given-names>T</given-names></name> <name><surname>Mokgalaboni</surname> <given-names>K</given-names></name> <name><surname>Nyambuya</surname> <given-names>TM</given-names></name> <etal/></person-group>. <article-title>Platelet activation in adult HIV-infected patients on antiretroviral therapy: a systematic review and meta-analysis</article-title>. <source>BMC Med</source>. (<year>2020</year>) <volume>18</volume>:<fpage>357</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12916-020-01801-9</pub-id>, PMID: <pub-id pub-id-type="pmid">33203400</pub-id></citation></ref>
<ref id="ref55"><label>55.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sperling</surname> <given-names>R</given-names></name></person-group>. <article-title>Zidovudine</article-title>. <source>Infect Dis Obstet Gynecol</source>. (<year>1998</year>) <volume>6</volume>:<fpage>197</fpage>&#x2013;<lpage>203</lpage>. doi: <pub-id pub-id-type="doi">10.1155/S1064744998000404</pub-id></citation></ref>
<ref id="ref56"><label>56.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ebrahim</surname> <given-names>O</given-names></name> <name><surname>Mazanderani</surname> <given-names>AH</given-names></name></person-group>. <article-title>Recent developments in hiv treatment and their dissemination in poor countries</article-title>. <source>Infect Dis Rep</source>. (<year>2013</year>) <volume>5</volume>:<fpage>e2</fpage>. doi: <pub-id pub-id-type="doi">10.4081/idr.2013.s1.e2</pub-id>, PMID: <pub-id pub-id-type="pmid">24470966</pub-id></citation></ref>
<ref id="ref57"><label>57.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kajogoo</surname> <given-names>VD</given-names></name> <name><surname>Gorret Atim</surname> <given-names>M</given-names></name> <name><surname>Amare</surname> <given-names>D</given-names></name> <name><surname>Geleta</surname> <given-names>M</given-names></name> <name><surname>Muchie</surname> <given-names>Y</given-names></name> <name><surname>Tesfahunei</surname> <given-names>HA</given-names></name> <etal/></person-group>. <article-title>HIV protease inhibitors and insulin sensitivity: a systematic review and Meta-analysis of randomized controlled trials</article-title>. <source>Front Pharmacol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>635089</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2021.635089</pub-id>, PMID: <pub-id pub-id-type="pmid">34790115</pub-id></citation></ref>
<ref id="ref58"><label>58.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malindisa</surname> <given-names>E</given-names></name> <name><surname>Balandya</surname> <given-names>E</given-names></name> <name><surname>Njelekela</surname> <given-names>M</given-names></name> <name><surname>Kidenya</surname> <given-names>BR</given-names></name> <name><surname>Francis</surname> <given-names>F</given-names></name> <name><surname>Mmbaga</surname> <given-names>BT</given-names></name> <etal/></person-group>. <article-title>Metabolic syndrome among people living with HIV on antiretroviral therapy in Mwanza, Tanzania</article-title>. <source>BMC Endocr Disord</source>. (<year>2023</year>) <volume>23</volume>:<fpage>88</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12902-023-01340-3</pub-id>, PMID: <pub-id pub-id-type="pmid">37085806</pub-id></citation></ref>
<ref id="ref59"><label>59.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gallant</surname> <given-names>JE</given-names></name> <name><surname>Moore</surname> <given-names>RD</given-names></name></person-group>. <article-title>Renal function with use of a tenofovir-containing initial antiretroviral regimen</article-title>. <source>AIDS</source>. (<year>2009</year>) <volume>23</volume>:<fpage>1971</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1097/QAD.0b013e32832c96e9</pub-id>, PMID: <pub-id pub-id-type="pmid">19696652</pub-id></citation></ref>
<ref id="ref60"><label>60.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tourret</surname> <given-names>J</given-names></name> <name><surname>Deray</surname> <given-names>G</given-names></name> <name><surname>Isnard-Bagnis</surname> <given-names>C</given-names></name></person-group>. <article-title>Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?</article-title> <source>J Am Soc Nephrol</source>. (<year>2013</year>) <volume>24</volume>:<fpage>1519</fpage>&#x2013;<lpage>27</lpage>. doi: <pub-id pub-id-type="doi">10.1681/ASN.2012080857</pub-id>, PMID: <pub-id pub-id-type="pmid">24052632</pub-id></citation></ref>
<ref id="ref61"><label>61.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Venter</surname> <given-names>WDF</given-names></name> <name><surname>Fabian</surname> <given-names>J</given-names></name> <name><surname>Feldman</surname> <given-names>C</given-names></name></person-group>. <article-title>An overview of tenofovir and renal disease for the HIV-treating clinician</article-title>. <source>South Afr J HIV Med</source>. (<year>2018</year>) <volume>19</volume>:<fpage>817</fpage>. doi: <pub-id pub-id-type="doi">10.4102/sajhivmed.v19i1.817</pub-id></citation></ref>
<ref id="ref62"><label>62.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kalim</surname> <given-names>S</given-names></name> <name><surname>Szczech</surname> <given-names>LA</given-names></name> <name><surname>Wyatt</surname> <given-names>CM</given-names></name></person-group>. <article-title>Acute kidney injury in HIV-infected patients</article-title>. <source>Semin Nephrol</source>. (<year>2008</year>) <volume>28</volume>:<fpage>556</fpage>&#x2013;<lpage>62</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.semnephrol.2008.08.008</pub-id>, PMID: <pub-id pub-id-type="pmid">19013326</pub-id></citation></ref>
<ref id="ref63"><label>63.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>George</surname> <given-names>C</given-names></name> <name><surname>Echouffo-Tcheugui</surname> <given-names>JB</given-names></name> <name><surname>Jaar</surname> <given-names>BG</given-names></name> <name><surname>Okpechi</surname> <given-names>IG</given-names></name> <name><surname>Kengne</surname> <given-names>AP</given-names></name></person-group>. <article-title>The need for screening, early diagnosis, and prediction of chronic kidney disease in people with diabetes in low- and middle-income countries-a review of the current literature</article-title>. <source>BMC Med</source>. (<year>2022</year>) <volume>20</volume>:<fpage>247</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12916-022-02438-6</pub-id>, PMID: <pub-id pub-id-type="pmid">35915501</pub-id></citation></ref>
<ref id="ref64"><label>64.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>George</surname> <given-names>C</given-names></name> <name><surname>Mogueo</surname> <given-names>A</given-names></name> <name><surname>Okpechi</surname> <given-names>I</given-names></name> <name><surname>Echouffo-Tcheugui</surname> <given-names>JB</given-names></name> <name><surname>Kengne</surname> <given-names>AP</given-names></name></person-group>. <article-title>Chronic kidney disease in low-income to middle-income countries: the case for increased screening</article-title>. <source>BMJ Glob Health</source>. (<year>2017</year>) <volume>2</volume>:<fpage>e000256</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmjgh-2016-000256</pub-id>, PMID: <pub-id pub-id-type="pmid">29081996</pub-id></citation></ref>
<ref id="ref65"><label>65.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Duijl</surname> <given-names>TT</given-names></name> <name><surname>Ruhaak</surname> <given-names>LR</given-names></name> <name><surname>de Fijter</surname> <given-names>JW</given-names></name> <name><surname>Cobbaert</surname> <given-names>CM</given-names></name></person-group>. <article-title>Kidney injury biomarkers in an academic hospital setting: where are we now?</article-title> <source>Clin Biochem Rev</source>. (<year>2019</year>) <volume>40</volume>:<fpage>79</fpage>&#x2013;<lpage>97</lpage>. doi: <pub-id pub-id-type="doi">10.33176/AACB-18-00017</pub-id>, PMID: <pub-id pub-id-type="pmid">31205376</pub-id></citation></ref>
<ref id="ref66"><label>66.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yilma</surname> <given-names>D</given-names></name> <name><surname>Abdissa</surname> <given-names>A</given-names></name> <name><surname>K&#x00E6;stel</surname> <given-names>P</given-names></name> <name><surname>Tesfaye</surname> <given-names>M</given-names></name> <name><surname>Olsen</surname> <given-names>MF</given-names></name> <name><surname>Girma</surname> <given-names>T</given-names></name> <etal/></person-group>. <article-title>Serum creatinine and estimated glomerular filtration rates in HIV positive and negative adults in Ethiopia</article-title>. <source>PLoS One</source>. (<year>2019</year>) <volume>14</volume>:<fpage>e0211630</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0211630</pub-id>, PMID: <pub-id pub-id-type="pmid">30753190</pub-id></citation></ref>
<ref id="ref67"><label>67.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paton</surname> <given-names>NI</given-names></name> <name><surname>Musaazi</surname> <given-names>J</given-names></name> <name><surname>Kityo</surname> <given-names>C</given-names></name> <name><surname>Walimbwa</surname> <given-names>S</given-names></name> <name><surname>Hoppe</surname> <given-names>A</given-names></name> <name><surname>Balyegisawa</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>Dolutegravir or Darunavir in combination with zidovudine or Tenofovir to treat HIV</article-title>. <source>N Engl J Med</source>. (<year>2021</year>) <volume>385</volume>:<fpage>330</fpage>&#x2013;<lpage>41</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa2101609</pub-id></citation></ref>
<ref id="ref68"><label>68.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fantauzzi</surname> <given-names>A</given-names></name> <name><surname>Mezzaroma</surname> <given-names>I</given-names></name></person-group>. <article-title>Dolutegravir: clinical efficacy and role in HIV therapy</article-title>. <source>Ther Adv Chronic Dis</source>. (<year>2014</year>) <volume>5</volume>:<fpage>164</fpage>&#x2013;<lpage>77</lpage>. doi: <pub-id pub-id-type="doi">10.1177/2040622314530461</pub-id>, PMID: <pub-id pub-id-type="pmid">24982751</pub-id></citation></ref>
</ref-list>
</back>
</article>